Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Net Income towards Common Stockholders (2016 - 2024)

Historic Net Income towards Common Stockholders for Arcadia Biosciences (RKDA) over the last 11 years, with Q4 2024 value amounting to -$27000.0.

  • Arcadia Biosciences' Net Income towards Common Stockholders rose 9875.63% to -$27000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$27000.0, marking a year-over-year increase of 9944.51%. This contributed to the annual value of -$2.7 million for FY2024, which is 6527.57% up from last year.
  • Arcadia Biosciences' Net Income towards Common Stockholders amounted to -$27000.0 in Q4 2024, which was up 9875.63% from -$430000.0 recorded in Q3 2024.
  • In the past 5 years, Arcadia Biosciences' Net Income towards Common Stockholders ranged from a high of $7.6 million in Q4 2020 and a low of -$13.8 million during Q4 2021
  • Over the past 5 years, Arcadia Biosciences' median Net Income towards Common Stockholders value was -$1.7 million (recorded in 2023), while the average stood at -$2.7 million.
  • As far as peak fluctuations go, Arcadia Biosciences' Net Income towards Common Stockholders skyrocketed by 22027.56% in 2020, and later crashed by 71546.96% in 2024.
  • Arcadia Biosciences' Net Income towards Common Stockholders (Quarter) stood at $7.6 million in 2020, then plummeted by 281.77% to -$13.8 million in 2021, then surged by 91.68% to -$1.1 million in 2022, then crashed by 89.11% to -$2.2 million in 2023, then soared by 98.76% to -$27000.0 in 2024.
  • Its Net Income towards Common Stockholders was -$27000.0 in Q4 2024, compared to -$430000.0 in Q3 2024 and -$789000.0 in Q2 2024.